Clearmind Medicine Inc.
CMNDCIK 0001892500 · Pharmaceutical Preparations · Nasdaq
Revenue (TTM)
—
Q1 Jan 2026
Net Income (TTM)
−3.86M
+26.6% YoY
Q1 Jan 2026
EPS Diluted (TTM)
−13.28
+55.2% YoY
Q1 Jan 2026
Gross Margin
—
Q1 Jan 2026
Operating Margin
—
Q1 Jan 2026
Net Margin
—
Q1 Jan 2026
Free Cash Flow (TTM)
—
Q1 Jan 2026
Cash
9.26M
Q1 Jan 2026
Total Debt
—
Q1 Jan 2026
Shares Outstanding
158.08K sh
Q1 Jan 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.